ADTX News and Press, ADiTx Therapeutics Inc. From 03/02/23

A recent study has revealed that organ transplant patients of lower socioeconomic status are likely to be unvaccinated against pneumococcus and influenza. The study also found that area of residence affected whether or not solid organ transplant patients were suitably vaccinated against these t...

Consuming too much salt affects an individual’s cardiovascular system and blood pressure negatively while also impacting the immune system adversely. A new study has now found that the consumption of too much salt weakens the energy supply of regulatory T cells, preventing them from work...

Aditxt (NASDAQ: ADTX) , an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced the formation of a U.S.-based wholly owned subsidiary, Pearsanta Inc. The move intends to accelerate the expansion of Aditxtȁ...

AditxtScore™ continued driving revenue growth in 2022 by adding to its expanding customer base of large physician networks, healthcare systems, independent laboratories, and employer-sponsored programs. Aditxt, Inc. , (NASDAQ: ADTX) (“Aditxt” or the “Comp...

An estimated 32 million Americans, including 26 million adults and 5.6 million minors, live with a food allergy. For many of these Americans, their day-to-day lives involve avoiding certain foods that can trigger moderate to severe allergic reactions. However, subsisting on such a restricted ...

Aditxt (NASDAQ: ADTX) recently announced the formation of a U.S.-based wholly owned subsidiary, Adimune Inc., and appointed Joachim-Friedrich Kapp, MD, Ph.D, a 30-year veteran of the pharmaceutical industry, as its chairman and CEO. “Dr. Kapp will be tasked with leading and developing the...

Aditxt (NASDAQ: ADTX) , a biotech innovation company, is developing and commercializing technologies with a focus on monitoring and modulating, mapping and reprogramming the immune system, designing technologies to provide a personalized immune profile. “In late October 2022, Aditxt announ...

Aditxt recently announced the formation of a U.S.-based wholly owned subsidiary, Adimune, Inc., and appointed Joachim-Friedrich Kapp, M.D., Ph.D., a 30-year veteran of the pharmaceutical industry, as its Chairman and CEO Dr. Kapp will be tasked with leading and developing the Apoptotic DNA Immu...

Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. The company today announced the formation of a U.S.-based subsidiary Adimune Inc. (“Adimune(TM)”) and its plans towards sub...

Completion of GMP Drug Substances in January for Clinical Trials in H2, 2023 Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the im...